IS6973A - Notkun pýrasólínafleiða í framleiðslu á lyfi til að fyrirbyggja og/eða meðhöndla frumufjölgunarsjúkdóma - Google Patents

Notkun pýrasólínafleiða í framleiðslu á lyfi til að fyrirbyggja og/eða meðhöndla frumufjölgunarsjúkdóma

Info

Publication number
IS6973A
IS6973A IS6973A IS6973A IS6973A IS 6973 A IS6973 A IS 6973A IS 6973 A IS6973 A IS 6973A IS 6973 A IS6973 A IS 6973A IS 6973 A IS6973 A IS 6973A
Authority
IS
Iceland
Prior art keywords
methyl
hydrogen
trifluoromethyl
fluorine
aminosulphonyl
Prior art date
Application number
IS6973A
Other languages
English (en)
Inventor
Rosa Cuberes-Altisent María
María Berrocal-Romero Juana
Montserrat Contijoch-Llobet María
Frigola-Constansa Jordi
Original Assignee
Laboratorios Del Dr. Esteve, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Del Dr. Esteve, S.A. filed Critical Laboratorios Del Dr. Esteve, S.A.
Publication of IS6973A publication Critical patent/IS6973A/is

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IS6973A 2001-04-06 2003-10-03 Notkun pýrasólínafleiða í framleiðslu á lyfi til að fyrirbyggja og/eða meðhöndla frumufjölgunarsjúkdóma IS6973A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200100818A ES2174757B1 (es) 2001-04-06 2001-04-06 Empleo de derivados de firazolinas en la elaboracion de un medicamentopara la prevencion y/o el tratamiento de enfermedades proliferativas celulares.
PCT/ES2002/000137 WO2002080909A1 (es) 2001-04-06 2002-03-21 Empleo de derivados de pirazolinas en la elaboración de un medicamento para la prevención y/o el tratamiento de enfermedades proliferativas celulares

Publications (1)

Publication Number Publication Date
IS6973A true IS6973A (is) 2003-10-03

Family

ID=8497370

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6973A IS6973A (is) 2001-04-06 2003-10-03 Notkun pýrasólínafleiða í framleiðslu á lyfi til að fyrirbyggja og/eða meðhöndla frumufjölgunarsjúkdóma

Country Status (26)

Country Link
US (1) US20040034082A1 (is)
EP (2) EP1516621A3 (is)
JP (1) JP4451599B2 (is)
KR (1) KR20040025912A (is)
CN (2) CN1698602A (is)
AT (1) ATE326966T1 (is)
AU (1) AU2002246152B2 (is)
BR (1) BR0208805A (is)
CA (1) CA2442974C (is)
CY (1) CY1105523T1 (is)
DE (1) DE60211681T2 (is)
DK (1) DK1384477T3 (is)
ES (2) ES2174757B1 (is)
HU (1) HUP0400918A3 (is)
IL (1) IL158269A0 (is)
IS (1) IS6973A (is)
MA (1) MA27019A1 (is)
MX (1) MXPA03009124A (is)
NO (1) NO20034470L (is)
NZ (1) NZ529304A (is)
PL (1) PL365220A1 (is)
PT (1) PT1384477E (is)
RU (1) RU2305545C2 (is)
UA (1) UA75402C2 (is)
WO (1) WO2002080909A1 (is)
ZA (1) ZA200308626B (is)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2238923B1 (es) * 2004-02-16 2006-11-01 Laboratorios Del Dr. Esteve, S.A. Nuevos derivados pirazolinicos sustituidos.
EP1718618A1 (en) * 2004-02-16 2006-11-08 Laboratorios del Dr. Esteve S.A. Pyrazoline derivatives useful for the treatment of cancer
EP1637522A1 (en) * 2004-09-16 2006-03-22 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds for reducing triglycerides in blood
AU2005212817A1 (en) * 2004-02-17 2005-08-25 Laboratorios Dr. Esteve S.A. Substituted pyrazoline compounds for reducing triglycerides in blood
US7998996B2 (en) 2004-02-17 2011-08-16 Laboratorios Del Dr. Esteve S.A. Substituted pyrazoline compounds for reducing triglycerides in blood
TW200533657A (en) 2004-02-17 2005-10-16 Esteve Labor Dr Substituted pyrazoline compounds, their preparation and use as medicaments
EP1849776A1 (en) * 2006-04-26 2007-10-31 Laboratorios Del Dr. Esteve, S.A. Azepane- or Azocane-substituted pyrazoline compounds, their preparation and use as medicaments
EP1749525A1 (en) * 2005-07-15 2007-02-07 Laboratorios Del Dr. Esteve, S.A. Combination of substituted pyrazolines and anti-addictive agent
US7897589B2 (en) 2005-07-15 2011-03-01 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
EP1743890A1 (en) 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. 4,5-Dihydro-1H-pyrazole derivatives, their preparation and use as medicaments
ES2336883B1 (es) * 2005-07-15 2011-03-22 Laboratorios Del Dr. Esteve, S.A. Compuestos de pirazolina sustituidos, con una estereoquimica predeterminada, para la reduccion de trigliceridos en sangre.
EP1746090A1 (en) * 2005-07-15 2007-01-24 Laboratorios del Dr. Esteve S.A. Sustituted pyrazoline compounds, having predetermined stereochemistry, for reducing triglycerides in blood
ES2327203B1 (es) * 2005-07-15 2010-06-07 Laboratorios Del Dr. Esteve, S.A. Uso de compuestos de pirazolina sustituidos para el tratamiento de trastornos relacionados con la coagulacion.
WO2007009701A2 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome
EP1749527A1 (en) * 2005-07-15 2007-02-07 Laboratorios Del Dr. Esteve, S.A. Use of substituted pyrazoline compounds for the treatment of the lipid parameters of the metabolic syndrome
EP1743637A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome
WO2007009704A2 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Use of substituted pyrazoline compounds for the treatment of food disorders, including obesity or metabolic syndrome in patients with developed diabetes
EP1743889A1 (en) * 2005-07-15 2007-01-17 Laboratorios del Dr. Esteve S.A. Sustituted pyrazoline compounds, having predetermined stereochemistry, for reducing triglycerides in blood
EP1849784A1 (en) * 2006-04-26 2007-10-31 Laboratorios Del Dr. Esteve, S.A. Indoline-substituted pyrazoline compounds, their preparation and use as medicaments
WO2007009693A1 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr.Esteve, S.A Combination of a substituted pyrazoline compound and a drug used in food-related disorders
WO2007009703A2 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. New formulations of substituted pyrazoline compounds
ES2327379B1 (es) * 2005-07-15 2010-05-28 Laboratorios Del Dr. Esteve, S.A. Compuestos de pirazolina indolinsustituidos, su preparacion y su uso como medicamentos.
ES2326857B1 (es) * 2005-07-15 2010-05-11 Laboratorios Del Dr. Esteve, S.A. Uso de compuestos de pirazolina sustituidos para el tratamiento de los parametros lipidicos del sindrome metabolico.
EP1743642A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Use of substituted pyrazoline compounds and their derivatives for the treatment of cannabinoid system-associated diseases
EP1749526A1 (en) * 2005-07-15 2007-02-07 Laboratorios Del Dr. Esteve, S.A. Use of substituted pyrazoline compounds for the treatment of food disorders, including obesity or metabolic syndrome in patients with developed diabetes
ES2334967B1 (es) * 2005-07-15 2010-10-21 Laboratorios Del Dr. Esteve, S.A. Compuestos de pirazolina sustituidos, con una estereoquimica predeterminada, para la reduccion de trigliceridos en sangre.
EP1743892A1 (en) * 2005-07-15 2007-01-17 Laboratorios del Dr. Esteve S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
EP1743639A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Use of substituted pyrazoline compounds for the treatment of coagulation related diseases
EP1743643A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. New formulations of substituted pyrazoline compounds
WO2007009699A2 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A Use of substituted pyrazoline compounds and their derivatives for the treatment of cannabinoid system-associated diseases
EP1743636A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Combination of a substituted pyrazoline compound and a drug used in food-related disorders
ES2319074B1 (es) * 2005-07-15 2009-12-03 Laboratorios Del Dr. Esteve, S.A. Combinacion de principios activos.
KR101457637B1 (ko) * 2012-10-24 2014-11-20 건국대학교 산학협력단 디히드로피라졸카르보티오아미드 유도체 및 그 제법 및 그 유도체를 포함하는 항암제 조성물
CN103664785A (zh) * 2013-11-04 2014-03-26 南京大学 一类新颖的二氢吡唑磺胺衍生物的合成及在抗癌药物中的应用
US20230082841A1 (en) * 2021-09-14 2023-03-16 Maverick Gold (NV) LLC Methods and systems for titling and trading alternative reserves

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0674624T3 (da) * 1992-12-17 1999-09-13 Pfizer Pyrazoler med CRF-antagonistisk aktivitet
ES2193609T3 (es) * 1993-11-30 2003-11-01 Searle & Co Pirazolil-bencenosulfonamidas sustituidas y su uso como inhibidores de la ciclooxigenasa ii.
US5604253A (en) * 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
ES2137138B1 (es) * 1998-05-29 2000-09-16 Esteve Labor Dr Derivados de pirazolinas, su preparacion y su aplicacion como medicamentos.
AU771668C (en) * 1999-06-16 2005-08-11 Temple University - Of The Commonwealth System Of Higher Education 1-(4-sulfamylaryl)-3-substituted-5-aryl-2-pyrazolines as inhibitors of cyclooxygenase-2

Also Published As

Publication number Publication date
CA2442974C (en) 2010-02-23
ES2174757A1 (es) 2002-11-01
JP2004525166A (ja) 2004-08-19
NO20034470D0 (no) 2003-10-06
HUP0400918A2 (hu) 2004-07-28
EP1516621A2 (en) 2005-03-23
BR0208805A (pt) 2004-07-13
AU2002246152B2 (en) 2007-05-31
WO2002080909A1 (es) 2002-10-17
US20040034082A1 (en) 2004-02-19
IL158269A0 (en) 2004-05-12
NZ529304A (en) 2006-02-24
CN1698602A (zh) 2005-11-23
PL365220A1 (en) 2004-12-27
ES2264723T3 (es) 2007-01-16
HUP0400918A3 (en) 2004-10-28
EP1516621A3 (en) 2005-05-04
DK1384477T3 (da) 2006-08-21
CN1299682C (zh) 2007-02-14
DE60211681T2 (de) 2007-05-16
RU2305545C2 (ru) 2007-09-10
DE60211681D1 (de) 2006-06-29
ZA200308626B (en) 2004-11-05
CY1105523T1 (el) 2010-07-28
EP1384477A1 (en) 2004-01-28
HK1067311A1 (en) 2005-04-08
MA27019A1 (fr) 2004-12-20
JP4451599B2 (ja) 2010-04-14
KR20040025912A (ko) 2004-03-26
EP1384477B1 (en) 2006-05-24
MXPA03009124A (es) 2005-04-11
PT1384477E (pt) 2006-09-29
ATE326966T1 (de) 2006-06-15
ES2174757B1 (es) 2003-11-01
CA2442974A1 (en) 2002-10-17
CN1509171A (zh) 2004-06-30
RU2003132457A (ru) 2005-04-10
NO20034470L (no) 2003-12-05
UA75402C2 (en) 2006-04-17

Similar Documents

Publication Publication Date Title
IS6973A (is) Notkun pýrasólínafleiða í framleiðslu á lyfi til að fyrirbyggja og/eða meðhöndla frumufjölgunarsjúkdóma
NZ508990A (en) Pyrazoline derivatives, their preparation and application as medicaments
DK1109813T3 (da) Pyrroloindoler, pyridoindoler og azepinoindoler som 5-HT2C-agonister
DE69915519D1 (en) Pyrazolopyridine
MY126951A (en) Beta2-adrenoceptor agonists
DK0745596T3 (da) Heteroaromatiske oxazolforbindelser og anvendelse deraf
MXPA05004779A (es) Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesis.
MY119689A (en) Pyrazolopyridine derivatives
DE60032482D1 (de) 5-cyano-2-aminopyrimidine derivate
PE20030332A1 (es) Terapia de combinacion para el tratamiento del cancer
DK0637586T3 (da) 2-(Piperidin-4-yl, pyridin-4-yl og tetrahydropyridin-4-yl)-benzofuran-7-carbamatderivater, deres fremstilling og anvendelse
PT1202954E (pt) Novas aminobenzofenonas
HUP9904086A2 (hu) 4-es Helyzetben szubsztituált piperidinszármazékok és a vegyületeket tartalmazó gyógyszerkészítmények
NO941516L (no) 3-kinolylsubstituerte dihydropyridiner, fremgangsmåter for deres fremstilling og deres anvendelse
MXPA04004307A (es) Derivados de fenoxi-n-`4-(1,1-dioxoisotiazolidin-2-il)fenil-valeramida y otros compuestos como inhibidores del factor de coagulacion xa para el tratamiento de enfermedades tromboembolicas y tumores.
MXPA03002914A (es) Compuestos quimicos.
NZ336969A (en) Substituted 4-aminoalkoxy-1H-benzimidazole derivatives useful as dopamine autoreceptor (D2) agonists
DK1049670T3 (da) Azetidincarboxamidderivater til behandling af CNS-lidelser